The development of nanobody therapeutics has been growing rapidly in recent years, and at Yaohai Bio-Pharma, we have closely observed this trend. As a specialized CRDMO and biologics CDMO company, we provide comprehensive microbial expression system services using both E.coli and yeast. Our mission is to support biotech companies in advancing from laboratory research to clinical sample production and commercial-scale manufacturing. The demand for nanobody production has accelerated, requiring flexible platforms, high-quality standards, and fast project execution, all of which we focus on delivering through our integrated services.
Advantages of Our Nanobody Production
Our nanobody production capabilities benefit from years of project experience and a dedicated team. We have successfully managed over a hundred projects, including dual filings in China and the US, as well as clinical phases ranging from I to II. With scalable microbial fermentation and purification lines, including 50L to 2000L capacities, we ensure that each project is executed efficiently. Our dual expression platforms in E.coli and Pichia pastoris allow clients to select the optimal host for their nanobody, reducing trial-and-error time. These features make our CRDMO services particularly suitable for emerging biologics that require rapid and reliable scale-up.
Quality Control and Compliance
Maintaining product quality is a top priority at Yaohai Bio-Pharma. Our Quality Control Platform provides full analytical support, including raw material testing, in-process control, release testing, and stability studies. This ensures that all nanobody products meet regulatory requirements and industry standards. Compliance with GMP and international regulations is embedded throughout our workflows, allowing biotech partners to proceed confidently from development to clinical evaluation. By combining our technical expertise with a robust quality system, we help clients achieve consistent and reproducible biologics production.
Collaborative Project Management
At our biologics CDMO company, we emphasize a client-centered approach. Each nanobody project is paired with a dedicated project manager who monitors milestones, manages risks, and coordinates cross-functional teams. Our professionals provide guidance from gene engineering and strain construction to process optimization, IND submission support, and clinical sample production. This level of involvement ensures that each stage is delivered on time, within budget, and with the highest standards. Knowledge protection is strictly maintained to safeguard client’s intellectual property.
Conclusion: Supporting the Future of Nanobody Therapeutics
In conclusion, the rise of nanobody production highlights the importance of a reliable CRDMO partner. Yaohai Bio-Pharma combines scalable microbial expression platforms, dual-host flexibility, and a rigorous Quality Control Platform to accelerate biologics development. By integrating compliance, efficiency, and expert project management, we empower biotech companies to transition seamlessly from laboratory research to clinical and commercial production. Our dedication ensures that clients can bring innovative nanobody therapeutics to patients safely and efficiently.
